Xtandi — Medica
Prostate Cancer – Non-Metastatic, Castration-Sensitive
Initial criteria
- age ≥ 18 years
- patient has biochemical recurrence and is at high risk for metastasis (prostate-specific antigen doubling time ≤ 9 months)
Approval duration
1 year